Overview

Study to Compare the Level of Elafibranor in Blood After Repeat Administration in Japanese and Non-Asian Healthy Participants

Status:
Not yet recruiting
Trial end date:
2022-12-23
Target enrollment:
Participant gender:
Summary
This study is intended to measure the blood levels of Elafibranor and one of its metabolites in Japanese and non-Asian Healthy Participants, to be able to compare how the body absorbs, distributes, and eliminates Elafibranor after Repeat Administration, in order to support inclusion of Japanese patients in the planned clinical studies with elafibranor.
Phase:
Phase 1
Details
Lead Sponsor:
Ipsen